Why should you receive
hematopoietic stem cell transplantation in AMC?

Hematopoietic stem cell transplantation (HSCT) is used to treat malignant hematologic disorders (e.g. leukemia, lymphoma, multiple myeloma, etc.), solid malignant tumors, benign hematologic disorders (e.g. aplastic anemia, paroxysmal nocturnal hemoglobinuria, etc.), and other congenital immune and genetic disorders. It is largely distinguished by autologous and allogeneic hematopoietic stem cell transplantation. Autologous transplantation is transplantation of patient's hematopoietic stem cells, and allogeneic transplantation is transplantation of the stem cells and the family or other people.

Beginning from 1993 and up to 2016, AMC has performed 1,400 autologous hematopoietic stem cell transplantations and 2,300 allogeneic hematopoietic stem cell transplantations. Hematopoietic stem cell transplantation involves conditioning regimen or radiation therapy, injecting hematopoietic stem cells (HSC), post-transplant care, and complication treatment. It requires effective chemotherapy, superior technologies to collect and store HSC, precise infection control, and quality nursing care. AMC’s departments of hematology, oncology, and pediatric hematology & oncology strive to provide optimized hematopoietic stem cell transplantation and post-transplant care for each patient and are actively engaged in clinical research projects.

In particular, AMC is the most active center for haploidentical hematopoietic stem cell transplantation in Korea, and the effort has paid off with world-class achievements in haploidentical hematopoietic stem cell transplantation by minimizing complications with an advanced T-cell removal technique and lowering the relapse rate through a combination of immunotherapy with hematopoietic stem cell transplantation for malignant diseases.